---
title: "Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program | SNTI Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286418645.md"
description: "Senti Biosciences Holdings has announced a positive outcome from its FDA RMAT meeting regarding the registrational clinical and CMC strategy for SENTI-202, aimed at treating relapsed/refractory AML. The company also provided significant updates on the efficacy and durability of the SENTI-202 clinical program."
datetime: "2026-05-14T04:40:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286418645.md)
  - [en](https://longbridge.com/en/news/286418645.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286418645.md)
generator: "portal-rs"
---

# Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program | SNTI Stock News

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program | SNTI Stock News

### Related Stocks

- [SNTI.US](https://longbridge.com/en/quote/SNTI.US.md)

## Related News & Research

- [DHT Holdings (DHT) Faces Dividend Durability Questions As Valuation Looks Fully Valued](https://longbridge.com/en/news/298240860.md)
- [KURA: KOMZIFTI leads new patient starts in acute leukemia, with major data and expansion ahead](https://longbridge.com/en/news/298474937.md)
- [Should Distribution Hold Require Action From Icahn Enterprises (IEP) Investors?](https://longbridge.com/en/news/298826260.md)
- [SNDX: Dominant AML market share, advancing pivotal trials, and expanding pipeline in oncology and fibrosis](https://longbridge.com/en/news/298611451.md)
- [MANE: Extended-release oral minoxidil shows promise for FDA approval in both male and female hair loss](https://longbridge.com/en/news/298498192.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**